Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target Raised to $58.00

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price objective hoisted by Wedbush from $53.00 to $58.00 in a report released on Thursday morning,Benzinga reports. Wedbush currently has an outperform rating on the stock.

Several other analysts have also weighed in on the company. Zacks Research upgraded Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 25th. Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, January 22nd. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. Wells Fargo & Company raised their price objective on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Finally, Canaccord Genuity Group assumed coverage on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, February 19th. They issued a “buy” rating and a $62.00 price objective on the stock. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, Kiniksa Pharmaceuticals International currently has an average rating of “Moderate Buy” and a consensus target price of $56.00.

Kiniksa Pharmaceuticals International Price Performance

Shares of NASDAQ:KNSA opened at $44.90 on Thursday. Kiniksa Pharmaceuticals International has a 12 month low of $19.62 and a 12 month high of $50.03. The stock has a market cap of $3.44 billion, a price-to-earnings ratio of 60.68 and a beta of 0.06. The stock’s 50 day moving average price is $46.18 and its 200 day moving average price is $42.63.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, February 24th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.12). Kiniksa Pharmaceuticals International had a net margin of 8.71% and a return on equity of 11.48%. The firm had revenue of $202.13 million for the quarter, compared to the consensus estimate of $200.86 million. During the same period in the previous year, the business posted ($0.12) earnings per share. The business’s revenue for the quarter was up 65.0% compared to the same quarter last year. On average, sell-side analysts expect that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current year.

Insider Transactions at Kiniksa Pharmaceuticals International

In other news, CEO Sanj K. Patel sold 7,278 shares of Kiniksa Pharmaceuticals International stock in a transaction on Monday, April 6th. The stock was sold at an average price of $50.01, for a total transaction of $363,972.78. Following the transaction, the chief executive officer owned 7,278 shares in the company, valued at approximately $363,972.78. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ross Moat sold 2,367 shares of Kiniksa Pharmaceuticals International stock in a transaction on Monday, April 6th. The shares were sold at an average price of $48.58, for a total value of $114,988.86. Following the transaction, the chief operating officer owned 12,029 shares in the company, valued at $584,368.82. This represents a 16.44% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 61,479 shares of company stock worth $2,832,812. 53.48% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of institutional investors have recently bought and sold shares of the business. Mark Sheptoff Financial Planning LLC increased its holdings in shares of Kiniksa Pharmaceuticals International by 1.6% in the 4th quarter. Mark Sheptoff Financial Planning LLC now owns 16,350 shares of the company’s stock valued at $674,000 after purchasing an additional 250 shares during the period. Mariner LLC grew its position in Kiniksa Pharmaceuticals International by 2.0% during the fourth quarter. Mariner LLC now owns 13,519 shares of the company’s stock valued at $558,000 after purchasing an additional 266 shares in the last quarter. Virtus Investment Advisers LLC grew its position in Kiniksa Pharmaceuticals International by 2.5% during the fourth quarter. Virtus Investment Advisers LLC now owns 16,432 shares of the company’s stock valued at $678,000 after purchasing an additional 406 shares in the last quarter. Mercer Global Advisors Inc. ADV increased its stake in Kiniksa Pharmaceuticals International by 7.1% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 7,684 shares of the company’s stock valued at $317,000 after buying an additional 508 shares during the period. Finally, EverSource Wealth Advisors LLC increased its stake in Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after buying an additional 532 shares during the period. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.